Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART4215 in advanced or metastatic solid tumors
NCT04991480Phase 1Completed
- Sponsor
- Artios Pharma
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of art4215 in cancer, metastatic cancer and breast cancer (6 arms), sponsored by Artios Pharma. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and 1 more. Started Sep 2021; status: completed.
02
Drugs
art4215
03
Conditions
cancermetastatic cancerbreast cancer
Beyond the preview
Go deeper on NCT04991480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991480.